Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results
April 29, 2015 6:00 AM EDTLAVAL, Quebec, April 29, 2015 /PRNewswire/ --
2015 First Quarter Results
Total Revenue $2.2 billion; an increase of 16% over the prior year despite negative foreign exchange impact of $140 million Excluding negative impact of foreign exchange and last year's divestiture of the aesthetics injectable business, revenue increased 27% over the prior year Same Store Sales Organic Growth was 15%, driven by: Growth from launch brands, including BioTrue Multipurpose Solution, BioTrue ONEday Contact Lens, Jublia, Luzu, and Ultra Contact Lens Double digit... MoreValeant Announces CFO Succession Plan And Additional Executive Appointment
April 29, 2015 6:00 AM EDTLAVAL, Quebec, April 29, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. Â With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued recommendation,... More
